From Syndax Pockets $26.6M For Final Stage Push With Cancer Drug:

Syndax Pharmaceuticals

Syndax Pharmaceuticals—

Syndax Pharmaceuticals develops drugs for cancer.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
IBM Watson Health Data in Action – Epidemiology Studies
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Xconomy on Demand

We offer a number of ways to subscribe for free!